{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:50:39Z","timestamp":1775062239111,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,21]]},"DOI":"10.7759\/cureus.35261","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T10:02:12Z","timestamp":1676973732000},"source":"Crossref","is-referenced-by-count":10,"title":["Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant"],"prefix":"10.7759","author":[{"given":"Rajesh P","family":"Karyakarte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmita","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Dudhate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Agarasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveena","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka M","family":"Chandankhede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutika S","family":"Labhshetwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogita","family":"Gadiyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansi V","family":"Rajmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeti P","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safanah","family":"Nizarudeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suvarna","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Potdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishanpal","family":"Karmodiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade C","year":"2022","unstructured":"Kurhade C, Zou J, Xia H, et al.. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2022, 29:344-7. 10.1038\/s41591-022-02162-x","journal-title":"Nat Med"},{"key":"ref2","unstructured":"Weekly epidemiological update on COVID-19 - 19 January 2023. (2023). Accessed. January 24, 2023: https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---19-january-2023."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-03445-6","article-title":"COVID 'variant soup' is making winter surges hard to predict","volume":"611","author":"Callaway E","year":"2022","unstructured":"Callaway E. COVID 'variant soup' is making winter surges hard to predict. Nature. 2022, 611:213-4. 10.1038\/d41586-022-03445-6","journal-title":"Nature"},{"key":"ref4","unstructured":"Proposal for a sublineage of BA.5.2.1 with S.R346T and N:S33F (originally proposed by @FedeGueli) #827 . (2022). Accessed: February 15, 2023: https:\/\/github.com\/cov-lineages\/pango-designation\/issues\/827."},{"key":"ref5","unstructured":"BQ.1* Omicron (BQ.1.X) variant report. (2023). Accessed. January 24, 2023: https:\/\/outbreak.info\/situation-reports\/BQ.1*%20%5BOmicron%20(BQ.1.X)%5D?xmin=2022-08-21&xmax=2023-02-21&loc=USA&loc=...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang Q","year":"2023","unstructured":"Wang Q, Iketani S, Li Z, et al.. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023, 186:279-86.e8. 10.1016\/j.cell.2022.12.018","journal-title":"Cell"},{"key":"ref7","unstructured":"BA.2 with ORF1b.S959P [50% in India, 3% of global BA.2] #496 . (2022). Accessed: February 15, 2023: https:\/\/github.com\/cov-lineages\/pango-designation\/issues\/496."},{"key":"ref8","unstructured":"XBB.1 lineage report. (2023). Accessed. January 24, 2023: https:\/\/outbreak.info\/situation-reports?xmin=2022-07-25&xmax=2023-01-25&pango=XBB.1."},{"key":"ref9","unstructured":"XBB.1.5* lineage report. (2023). Accessed. January 24, 2023:  https:\/\/outbreak.info\/situation-reports\/XBB.1.5*%20%5BOmicron%20(XBB.1.5.X)%5D?xmin=2022-07-25&xmax=2023-01-25."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01887-z","article-title":"Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1\/BA.1.1 or BA.2 subvariant infection in Southern California","volume":"28","author":"Lewnard JA","year":"2022","unstructured":"Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1\/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med. 2022, 28:1933-43. 10.1038\/s41591-022-01887-z","journal-title":"Nat Med"},{"key":"ref11","unstructured":"SARS-CoV-2 evolution, post-Omicron. (2023). Accessed. December 30, 2022:  https:\/\/virological.org\/t\/sars-cov-2-evolution-post-omicron\/911."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.08.014","article-title":"Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic","volume":"184","author":"Jackson B","year":"2021","unstructured":"Jackson B, Boni MF, Bull MJ, et al.. Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell. 2021, 184:5179-88.e8. 10.1016\/j.cell.2021.08.014","journal-title":"Cell"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1502293\/v1","article-title":"Rapid characterisation of a delta-Omicron SARS-CoV-2 recombinant detected in Europe","author":"Simon-Loriere E","year":"2022","unstructured":"Simon-Loriere E, Montagutelli X, Lemoine F, et al.. Rapid characterisation of a delta-Omicron SARS-CoV-2 recombinant detected in Europe. ResearchSquare. 2022, 10.21203\/rs.3.rs-1502293\/v1","journal-title":"ResearchSquare"},{"key":"ref14","unstructured":"Release pango designations V1.17. COV-lineages\/pango-designation. (2022). Accessed. January 2, 2023: https:\/\/github.com\/cov-lineages\/pango-designation\/releases\/tag\/v1.17."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00010-5","article-title":"ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5 [in press]","author":"Yue C","year":"2023","unstructured":"Yue C, Song W, Wang L, et al.. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5 [in press]. Lancet Infect Dis. 2023, 10.1016\/S1473-3099(23)00010-5","journal-title":"Lancet Infect Dis"},{"key":"ref16","unstructured":"Lineage comparison. (2023). Accessed. January 24, 2023: https:\/\/outbreak.info\/compare-lineages?pango=BJ.1&pango=BM.1.1.1&pango=XBB&pango=XBB.1&pango=XBB.1.1&pango=XBB.1.3&pa...."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.27.521986","article-title":"Virological characteristics of the SARS-COV-2 XBB variant derived from recombination of two Omicron subvariants","author":"Tamura T","year":"2022","unstructured":"Tamura T, Ito J, Uriu K, et al.. Virological characteristics of the SARS-COV-2 XBB variant derived from recombination of two Omicron subvariants. bioRxiv. 2022, 10.1101\/2022.12.27.521986","journal-title":"bioRxiv"},{"key":"ref18","unstructured":"BA.2.75* [Omicron (BA.2.75.X)] variant report. (2023). Accessed. January 24, 2023: https:\/\/outbreak.info\/situation-reports\/BA.2.75*%20%5BOmicron%20(BA.2.75.X)%5D?selected=IND&loc=USA&loc=USA_US-CA&loc...."},{"key":"ref19","unstructured":"XBB* (Nextclade)-India. (2023). Accessed. January 24, 2023: https:\/\/cov-spectrum.org\/explore\/India\/AllSamples\/Past6M\/variants?nextcladePangoLineage=XBB*&."},{"key":"ref20","unstructured":"BA.2.38 lineage report. (2023). Accessed. January 24, 2023: https:\/\/outbreak.info\/situation-reports?pango=BA.2.38&selected=IND&loc=USA&loc=USA_US-CA&loc=IND&overlay=false."},{"key":"ref21","unstructured":"BA.2.10 lineage report. (2023). Accessed. January 24, 2023: https:\/\/outbreak.info\/situation-reports?pango=BA.2.10&selected=IND&loc=USA&loc=USA_US-CA&loc=IND&overlay=false."},{"key":"ref22","unstructured":"BA.5* [Omicron (BA.5.X)] variant report. (2023). Accessed. January 24, 2023: https:\/\/outbreak.info\/situation-reports\/BA.5*%20%5BOmicron%20(BA.5.X)%5D."},{"key":"ref23","unstructured":"India variant report. (2023). Accessed. January 24, 2023: https:\/\/outbreak.info\/location-reports?xmin=2022-07-24&xmax=2023-01-24&loc=IND."},{"key":"ref24","unstructured":"XBB.1.5* (Nextclade)-World. (2023). Accessed. January 24, 2023: https:\/\/cov-spectrum.org\/explore\/World\/AllSamples\/from=2022-10-01&to=2023-01-25\/variants?nextcladePangoLineage=XBB.1....."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.22.525079","article-title":"Waning immunity against XBB.1.5 following bivalent mRNA boosters","author":"Lasrado N","year":"2023","unstructured":"Lasrado N, Collier AY, Miller J, et al.. Waning immunity against XBB.1.5 following bivalent mRNA boosters. bioRxiv. 2023, 10.1101\/2023.01.22.525079","journal-title":"bioRxiv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/138573-clinical-characteristics-and-outcomes-of-laboratory-confirmed-sars-cov-2-cases-infected-with-omicron-subvariants-and-the-xbb-recombinant-variant","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:51:32Z","timestamp":1707490292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/138573-clinical-characteristics-and-outcomes-of-laboratory-confirmed-sars-cov-2-cases-infected-with-omicron-subvariants-and-the-xbb-recombinant-variant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.35261","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.05.23284211","asserted-by":"object"}]},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,21]]}}}